Pelthos Therapeutics to merge with Castle Creek Biosciences in stock-and-milestone deal
The combined company would pair Pelthos' dermatology products with Castle Creek's gene therapy candidate D-Fi for a rare skin disease, with closing targeted by the end of the first quarter of 2027.
SEC filing